Palma, Gabriela
Khurshid, Faisal
Lu, Kevin
Woodward, Brian http://orcid.org/0000-0001-8842-3654
Husain, Hatim http://orcid.org/0000-0003-4228-0963
Article History
Received: 31 March 2021
Accepted: 22 September 2021
First Online: 29 November 2021
Competing interests
: Hatim Husain has received research funding from Roche Sequencing Solutions, Bristol Myers Squibb, Pfizer, and Eli Lilly, honorarium from AstraZeneca, Blueprint Medicine, and Janssen, and consulting or advisor roles with Foundation Medicine, Neogenomics, Merck, AstraZeneca, Blueprints Medicine, Mirati Therapeutics, Turning Point Therapeutics, and Takeda. All other authors have no relevant disclosures to report.